

Multiple Sclerosis Drugs-Global Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/M701CB121E6MEN.html>

Date: May 2018

Pages: 143

Price: US\$ 2,480.00 (Single User License)

ID: M701CB121E6MEN

Abstracts

Report Summary

Multiple Sclerosis Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Multiple Sclerosis Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Multiple Sclerosis Drugs 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Multiple Sclerosis Drugs worldwide, with company and product introduction, position in the Multiple Sclerosis Drugs market

Market status and development trend of Multiple Sclerosis Drugs by types and applications

Cost and profit status of Multiple Sclerosis Drugs, and marketing status

Market growth drivers and challenges

The report segments the global Multiple Sclerosis Drugs market as:

Global Multiple Sclerosis Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America

Europe

China

Japan

Rest APAC

Latin America

Global Multiple Sclerosis Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Oral

Injectable

Intravenous

Global Multiple Sclerosis Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Global Multiple Sclerosis Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Multiple Sclerosis Drugs Sales Volume, Revenue, Price and Gross Margin):

Biogen

Teva Pharmaceutical

Merck KGaA

Novartis

Bayer

Sanofi

Acorda Therapeutics

Questcor Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF MULTIPLE SCLEROSIS DRUGS

- 1.1 Definition of Multiple Sclerosis Drugs in This Report
- 1.2 Commercial Types of Multiple Sclerosis Drugs
 - 1.2.1 Oral
 - 1.2.2 Injectable
 - 1.2.3 Intravenous
- 1.3 Downstream Application of Multiple Sclerosis Drugs
 - 1.3.1 Hospital Pharmacy
 - 1.3.2 Retail Pharmacy
 - 1.3.3 Online Pharmacy
- 1.4 Development History of Multiple Sclerosis Drugs
- 1.5 Market Status and Trend of Multiple Sclerosis Drugs 2013-2023
 - 1.5.1 Global Multiple Sclerosis Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Multiple Sclerosis Drugs Market Status and Trend 2013-2023

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of Multiple Sclerosis Drugs 2013-2017
- 2.2 Sales Market of Multiple Sclerosis Drugs by Regions
 - 2.2.1 Sales Volume of Multiple Sclerosis Drugs by Regions
 - 2.2.2 Sales Value of Multiple Sclerosis Drugs by Regions
- 2.3 Production Market of Multiple Sclerosis Drugs by Regions
- 2.4 Global Market Forecast of Multiple Sclerosis Drugs 2018-2023
 - 2.4.1 Global Market Forecast of Multiple Sclerosis Drugs 2018-2023
 - 2.4.2 Market Forecast of Multiple Sclerosis Drugs by Regions 2018-2023

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Sales Volume of Multiple Sclerosis Drugs by Types
- 3.2 Sales Value of Multiple Sclerosis Drugs by Types
- 3.3 Market Forecast of Multiple Sclerosis Drugs by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Global Sales Volume of Multiple Sclerosis Drugs by Downstream Industry

4.2 Global Market Forecast of Multiple Sclerosis Drugs by Downstream Industry

CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

5.1 North America Multiple Sclerosis Drugs Market Status by Countries

- 5.1.1 North America Multiple Sclerosis Drugs Sales by Countries (2013-2017)
- 5.1.2 North America Multiple Sclerosis Drugs Revenue by Countries (2013-2017)
- 5.1.3 United States Multiple Sclerosis Drugs Market Status (2013-2017)
- 5.1.4 Canada Multiple Sclerosis Drugs Market Status (2013-2017)
- 5.1.5 Mexico Multiple Sclerosis Drugs Market Status (2013-2017)

5.2 North America Multiple Sclerosis Drugs Market Status by Manufacturers

5.3 North America Multiple Sclerosis Drugs Market Status by Type (2013-2017)

- 5.3.1 North America Multiple Sclerosis Drugs Sales by Type (2013-2017)
- 5.3.2 North America Multiple Sclerosis Drugs Revenue by Type (2013-2017)

5.4 North America Multiple Sclerosis Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

6.1 Europe Multiple Sclerosis Drugs Market Status by Countries

- 6.1.1 Europe Multiple Sclerosis Drugs Sales by Countries (2013-2017)
- 6.1.2 Europe Multiple Sclerosis Drugs Revenue by Countries (2013-2017)
- 6.1.3 Germany Multiple Sclerosis Drugs Market Status (2013-2017)
- 6.1.4 UK Multiple Sclerosis Drugs Market Status (2013-2017)
- 6.1.5 France Multiple Sclerosis Drugs Market Status (2013-2017)
- 6.1.6 Italy Multiple Sclerosis Drugs Market Status (2013-2017)
- 6.1.7 Russia Multiple Sclerosis Drugs Market Status (2013-2017)
- 6.1.8 Spain Multiple Sclerosis Drugs Market Status (2013-2017)
- 6.1.9 Benelux Multiple Sclerosis Drugs Market Status (2013-2017)

6.2 Europe Multiple Sclerosis Drugs Market Status by Manufacturers

6.3 Europe Multiple Sclerosis Drugs Market Status by Type (2013-2017)

- 6.3.1 Europe Multiple Sclerosis Drugs Sales by Type (2013-2017)
- 6.3.2 Europe Multiple Sclerosis Drugs Revenue by Type (2013-2017)

6.4 Europe Multiple Sclerosis Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE,

MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 7.1 Asia Pacific Multiple Sclerosis Drugs Market Status by Countries
 - 7.1.1 Asia Pacific Multiple Sclerosis Drugs Sales by Countries (2013-2017)
 - 7.1.2 Asia Pacific Multiple Sclerosis Drugs Revenue by Countries (2013-2017)
 - 7.1.3 China Multiple Sclerosis Drugs Market Status (2013-2017)
 - 7.1.4 Japan Multiple Sclerosis Drugs Market Status (2013-2017)
 - 7.1.5 India Multiple Sclerosis Drugs Market Status (2013-2017)
 - 7.1.6 Southeast Asia Multiple Sclerosis Drugs Market Status (2013-2017)
 - 7.1.7 Australia Multiple Sclerosis Drugs Market Status (2013-2017)
- 7.2 Asia Pacific Multiple Sclerosis Drugs Market Status by Manufacturers
- 7.3 Asia Pacific Multiple Sclerosis Drugs Market Status by Type (2013-2017)
 - 7.3.1 Asia Pacific Multiple Sclerosis Drugs Sales by Type (2013-2017)
 - 7.3.2 Asia Pacific Multiple Sclerosis Drugs Revenue by Type (2013-2017)
- 7.4 Asia Pacific Multiple Sclerosis Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 8.1 Latin America Multiple Sclerosis Drugs Market Status by Countries
 - 8.1.1 Latin America Multiple Sclerosis Drugs Sales by Countries (2013-2017)
 - 8.1.2 Latin America Multiple Sclerosis Drugs Revenue by Countries (2013-2017)
 - 8.1.3 Brazil Multiple Sclerosis Drugs Market Status (2013-2017)
 - 8.1.4 Argentina Multiple Sclerosis Drugs Market Status (2013-2017)
 - 8.1.5 Colombia Multiple Sclerosis Drugs Market Status (2013-2017)
- 8.2 Latin America Multiple Sclerosis Drugs Market Status by Manufacturers
- 8.3 Latin America Multiple Sclerosis Drugs Market Status by Type (2013-2017)
 - 8.3.1 Latin America Multiple Sclerosis Drugs Sales by Type (2013-2017)
 - 8.3.2 Latin America Multiple Sclerosis Drugs Revenue by Type (2013-2017)
- 8.4 Latin America Multiple Sclerosis Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 9.1 Middle East and Africa Multiple Sclerosis Drugs Market Status by Countries
 - 9.1.1 Middle East and Africa Multiple Sclerosis Drugs Sales by Countries (2013-2017)
 - 9.1.2 Middle East and Africa Multiple Sclerosis Drugs Revenue by Countries

(2013-2017)

9.1.3 Middle East Multiple Sclerosis Drugs Market Status (2013-2017)

9.1.4 Africa Multiple Sclerosis Drugs Market Status (2013-2017)

9.2 Middle East and Africa Multiple Sclerosis Drugs Market Status by Manufacturers

9.3 Middle East and Africa Multiple Sclerosis Drugs Market Status by Type (2013-2017)

9.3.1 Middle East and Africa Multiple Sclerosis Drugs Sales by Type (2013-2017)

9.3.2 Middle East and Africa Multiple Sclerosis Drugs Revenue by Type (2013-2017)

9.4 Middle East and Africa Multiple Sclerosis Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF MULTIPLE SCLEROSIS DRUGS

10.1 Global Economy Situation and Trend Overview

10.2 Multiple Sclerosis Drugs Downstream Industry Situation and Trend Overview

CHAPTER 11 MULTIPLE SCLEROSIS DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

11.1 Production Volume of Multiple Sclerosis Drugs by Major Manufacturers

11.2 Production Value of Multiple Sclerosis Drugs by Major Manufacturers

11.3 Basic Information of Multiple Sclerosis Drugs by Major Manufacturers

11.3.1 Headquarters Location and Established Time of Multiple Sclerosis Drugs Major Manufacturer

11.3.2 Employees and Revenue Level of Multiple Sclerosis Drugs Major Manufacturer

11.4 Market Competition News and Trend

11.4.1 Merger, Consolidation or Acquisition News

11.4.2 Investment or Disinvestment News

11.4.3 New Product Development and Launch

CHAPTER 12 MULTIPLE SCLEROSIS DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

12.1 Biogen

12.1.1 Company profile

12.1.2 Representative Multiple Sclerosis Drugs Product

12.1.3 Multiple Sclerosis Drugs Sales, Revenue, Price and Gross Margin of Biogen

12.2 Teva Pharmaceutical

12.2.1 Company profile

- 12.2.2 Representative Multiple Sclerosis Drugs Product
- 12.2.3 Multiple Sclerosis Drugs Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical
- 12.3 Merck KGaA
 - 12.3.1 Company profile
 - 12.3.2 Representative Multiple Sclerosis Drugs Product
 - 12.3.3 Multiple Sclerosis Drugs Sales, Revenue, Price and Gross Margin of Merck KGaA
- 12.4 Novartis
 - 12.4.1 Company profile
 - 12.4.2 Representative Multiple Sclerosis Drugs Product
 - 12.4.3 Multiple Sclerosis Drugs Sales, Revenue, Price and Gross Margin of Novartis
- 12.5 Bayer
 - 12.5.1 Company profile
 - 12.5.2 Representative Multiple Sclerosis Drugs Product
 - 12.5.3 Multiple Sclerosis Drugs Sales, Revenue, Price and Gross Margin of Bayer
- 12.6 Sanofi
 - 12.6.1 Company profile
 - 12.6.2 Representative Multiple Sclerosis Drugs Product
 - 12.6.3 Multiple Sclerosis Drugs Sales, Revenue, Price and Gross Margin of Sanofi
- 12.7 Acorda Therapeutics
 - 12.7.1 Company profile
 - 12.7.2 Representative Multiple Sclerosis Drugs Product
 - 12.7.3 Multiple Sclerosis Drugs Sales, Revenue, Price and Gross Margin of Acorda Therapeutics
- 12.8 Questcor Pharmaceuticals
 - 12.8.1 Company profile
 - 12.8.2 Representative Multiple Sclerosis Drugs Product
 - 12.8.3 Multiple Sclerosis Drugs Sales, Revenue, Price and Gross Margin of Questcor Pharmaceuticals

CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF MULTIPLE SCLEROSIS DRUGS

- 13.1 Industry Chain of Multiple Sclerosis Drugs
- 13.2 Upstream Market and Representative Companies Analysis
- 13.3 Downstream Market and Representative Companies Analysis

CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF MULTIPLE SCLEROSIS

DRUGS

- 14.1 Cost Structure Analysis of Multiple Sclerosis Drugs
- 14.2 Raw Materials Cost Analysis of Multiple Sclerosis Drugs
- 14.3 Labor Cost Analysis of Multiple Sclerosis Drugs
- 14.4 Manufacturing Expenses Analysis of Multiple Sclerosis Drugs

CHAPTER 15 REPORT CONCLUSION

CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE

- 16.1 Methodology/Research Approach
 - 16.1.1 Research Programs/Design
 - 16.1.2 Market Size Estimation
 - 16.1.3 Market Breakdown and Data Triangulation
- 16.2 Data Source
 - 16.2.1 Secondary Sources
 - 16.2.2 Primary Sources
- 16.3 Reference

I would like to order

Product name: Multiple Sclerosis Drugs-Global Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/M701CB121E6MEN.html>

Price: US\$ 2,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M701CB121E6MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970